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ABSTRACT 
Introduction: Persistent physical symptoms (PPS), also known as medically unexplained 
symptoms (MUS), and are associated with profound physical disability, psychological distress 
and high health care costs.  England’s annual National Health Service costs of attempting to 
diagnose and treat PPS amounts to approximately £3 billion.  Current treatment relies on a 
positive diagnosis, life-style advice and drug therapy.  However, many patients continue to 
suffer from ongoing symptoms and general practitioners (GPs) are challenged to find effective 
treatments.  Training GPs in basic cognitive behavioural skills and providing self-help materials 
to patients could be useful, but availability in primary care settings is limited. 
Methods and analysis: A cluster randomised waiting list, controlled trial will be conducted 
to assess the feasibility of an integrated approach to care in general practice.  Approximately 
240 patients with PPS will be recruited from 8-12 GP practices in London.  GP practices will 
be randomised to ‘integrated GP care plus treatment as usual’ or waiting list control.  
‘Integrated GP care plus treatment as usual’ will include GP training in cognitive behavioural 
skills, GP supervision and written and audio-visual materials for both GPs and participants.  
The primary objectives will be assessment of trial and intervention feasibility. Secondary 
objectives will include estimating the intra-cluster correlation coefficient for potential outcome 
measures for cluster effects in a sample size calculation. Feasibility parameters and 
identification of suitable primary and secondary outcomes for future trial evaluations will be 
assessed pre-randomisation and at 12 and 24 weeks post randomisation, using a mixed 
methods approach. 
Ethics and dissemination: Ethical approval was granted by the Camberwell St Giles Ethics 
Committee.  Results will be disseminated via peer reviewed publications and conference 
presentations. This trial will inform researchers, clinicians, patients and healthcare providers 
about the feasibility and potential cost-effectiveness of an integrated approach to managing 
PPS in primary care. 
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Trial Registration Number: NCT02444520; Overall trial status: Active; Recruitment status 
(since May 2015): No longer recruiting. 
Registry Name: ClinicalTrials.gov 
INTRODUCTION 
Medically unexplained symptoms (MUS) is an umbrella term referring to persistent bodily 
symptoms, which cannot be adequately explained by organic pathology.[1]  MUS are highly 
prevalent with approximately 10% to 49% of patients in primary care.[2, 3]  MUS are associated 
with significant functional impairment, psychological distress and high health care costs.[4, 5, 
6] Moreover, approximately 60% of patients have a comorbid psychiatric condition, including 
depression, anxiety and panic disorders.[7-9] The NHS in England is estimated to spend 
approximately £3 billion each year attempting to diagnose and treat MUS, which represented 
approximately 10% of the total NHS expenditure in 2008–2009.[10] 
 
Strengths and limitations of this study 
 
▪ PRINCE Primary is a cluster, randomised waiting list, controlled trial, designed to evaluate 
the acceptability and feasibility of an integrated General Practitioner (GP) approach to care 
for adults with persistent physical symptoms (PPS). 
▪ A new transdiagnostic approach to managing patients with PPS in general practice was 
developed, which includes offering a CPD-accredited basic cognitive behavioural skills 
training and audio visual and written learning materials for GPs.  Participants of GP practices 
randomised to ‘integrated GP care plus treatment as usual will receive tailored self-help 
materials. 
▪ This feasibility study is not powered to evaluate efficacy or cost-effectiveness of integrated 
GP care but intends to identify suitable primary outcomes for an adequately powered future 
evaluation trial. 
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The term MUS is commonly used in health care and research.  However, it has been 
argued that using the label persistent physical symptoms (PPS) may be more appropriate for 
a number of reasons.  Firstly, recent surveys indicated that people with such symptoms and 
healthy respondents preferred the term PPS, as it avoids mind-body dualism and has cross-
cultural relevance.[11, 12]  Secondly, it includes symptoms associated with medically 
diagnosed long-term conditions, such as diabetes, rheumatoid arthritis and multiple sclerosis, 
which may present co-morbidly with MUS.  Thirdly, it concurs with changes in the latest edition 
of the Diagnostic and Statistics Manual (DSM-5).  The DSM-5 has consolidated previous terms 
including somatization disorder, conversion disorder, and hypochondriasis into a new 
diagnostic term – Somatic Symptom Disorder (SSD). This refers to persistent (6 months) and 
clinically significant somatic complaints accompanied by excessive and disproportionate 
health-related thoughts, feelings and behaviours regarding the symptoms.[13]  In this paper, 
we will use the term PPS to refer to MUS. 
There is an accumulating body of evidence showing that cognitive behavioural 
interventions can reduce levels of symptoms and improve overall functioning in patients with 
PPS.  Cognitive behavioural therapy (CBT) has demonstrated both short-term and long-term 
efficacy with small to medium effect sizes for PPS.[14, 15]  Larger treatment effects have been 
reported for specific PPS syndromes, including non-cardiac chest pain[16, 17] and Irritable 
Bowel Syndrome (IBS) [18-20]. 
Research indicates that the way health care professionals deliver interventions and 
offer treatment to patients with PPS significantly affects health outcomes.  For instance, a 
previous randomised controlled trial (RCT) evaluated the effectiveness of an integrated 
approach in treating women with chronic pelvic pain in secondary care.  This involved an 
assessment of pain sensation, nociception, pain suffering and pain behaviour, followed by a 
discussion about possible physical, psychological, dietary and environmental contributions 
plus physiotherapy, versus routine laparoscopy.  The findings revealed that the integrated 
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approach was significantly more effective in reducing pelvic pain compared to routine 
laparoscopy.[21] 
Evidence supporting the efficacy of psychopharmacological interventions for PPS is 
less clear.  A previous Cochrane review on pharmacological interventions found low-quality 
evidence for the use of new-generation antidepressants (NGAs).   No evidence was found for 
other psychotropic drugs, including tricyclic antidepressants and antipsychotics.[22]  This 
suggests the need for further research investigating the effectiveness of non-pharmacological 
treatments in managing PPS, including psychosocial interventions. 
 General practitioners (GPs) play a major role in identifying and managing patients with 
PPS. The Royal College of General Practitioners (RCGP) emphasises the importance of GPs 
in helping patients with PPS to make sense of their symptoms by adopting a biopsychosocial 
approach to treatment.[23]  A previous randomised parallel group pilot trial investigated the 
feasibility (i.e. recruitment, retention and acceptability) of implementing a primary care 
Symptoms Clinic for patients with PPS.[24]  The Symptoms Clinic comprised a structured set 
of consultations delivered by a specially trained GP with a strong interest in PPS.  The 
intervention included exploring potential biological mechanisms underlying the PPS condition, 
empathetic support, and training patients in symptom-management (i.e. medication or 
cognitive behavioural techniques).  The results indicated that the Symptoms Clinic was 
acceptable to the majority of patients randomised to the intervention group and may have the 
potential to generate clinically significant benefits.  However, this pilot study did not assess 
feasibility parameters referring to GPs’ willingness to participate in the study and undergo 
specialised psychological training. Moreover, the intervention was carried out by only one GP, 
raising questions about the generalizability of the study. 
Managing patients with PPS can be highly challenging in general practice.  Although 
GPs recognise the treatment of PPS as a responsibility of primary care, previous studies show 
that GPs often feel powerless, frustrated and helpless when encountering these patients.[25, 
26]  One possible explanation for this is an epistemological incongruence between taught ideal 
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biomedical models of disease, and the reality of meeting patients presenting with subjective 
persistent physical symptoms, which cannot be fully explained by organic causes.[26]  
Furthermore, GPs frequently report that factors such as time constraints and the lack of 
psychological training prevents them from effectively addressing patients’ psychosocial needs 
and developing appropriate doctor-patient communication skills.[25] 
Taken together, there are four strands of evidence: 
1. Psychological interventions may help patients with longstanding PPS; 
2. The way in which investigations are carried out and offered to patients with PPS affects 
health outcomes and service costs; 
3. Psychopharmacological interventions (i.e. antidepressants) have shown no or only 
small effects on alleviating PPS; and 
4. GPs often feel helpless and ill-equipped to manage patients with PPS. 
RESEARCH OBJECTIVES 
This paper presents a study protocol for the Persistent Physical Symptoms Reduction 
Intervention: a System Change & Evaluation in Primary Care (PRINCE Primary) trial, which 
aims to assess the acceptability and feasibility of an integrated care approach in managing 
adult patients with PPS in primary care.  Commissioning Support for London piloted an 
integrated service model for PPS, which largely focused on commissioning and cost 
saving.[27]  We will build on this pilot study by  
a. Assessing the feasibility of trialling a new integrated approach towards the 
management of patients in primary care, using robust methods, namely a cluster 
randomised waiting list, controlled trial. 
b. Estimating the intra-cluster correlation coefficient (ICC) for potential outcome measures 
for cluster effects in a sample size calculation.  
c. Measuring patient satisfaction and patient reported outcomes; 
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d. Including a broad range of patient groups in primary care, including those with non-
cardiac chest pain, dizziness and fibromyalgia; 
e. Identifying suitable primary outcome measures for a future trial evaluation. 
METHODS AND ANALYSIS 
Study Design 
Two arm cluster randomised waiting list, controlled trial. 
Method 
Approximately two hundred and forty patients with PPS will be recruited from eight to twelve 
GP practices.  These GP practices will be randomised to either ‘integrated GP care plus 
treatment as usual’ or waiting list control.  GP practices randomised to ‘integrated GP care 
plus treatment as usual’ will include (i) GP training in cognitive behavioural techniques, (ii) GP 
supervision, (iii) audio visual material for GPs and (iv) self-help materials for participants.  GP 
practices randomised to the waiting list control arm will continue with treatment as usual.  The 
waiting list control arm will be crossed over at 28 weeks to give 4 weeks to collect measures. 
This will not be part of the RCT but will contribute to a separate long term follow up.  A selection 
of feasibility parameters will be investigated pre- randomisation. In addition, to identify suitable 
primary and secondary outcomes for future trial evaluations measures will be completed at 12 
and 24 weeks.  GPs who attend the offer of GP training will complete measures pre and post 
GP training. 
Setting 
GP practices and participants will be recruited from South London, England.  GP training will 
take place at GP practices.  Training will be delivered by clinicians based within King’s Health 
Partners. 
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Study Population 
GP Practices/GPs 
GP practices within South London which fulfil the following eligibility criteria will be recruited 
into the study. 
(i) At least 50% of GPs within the practice express an interest in completing the 
training workshop 
(ii) The Practice Manager, Partner or other authorised individual is able to give consent 
for the practice to take part in the study 
(iii) The practice is not at risk of closure within the next year 
Patients 
Patients that fit the eligibility criteria will be invited to take part in the study.  Patients will be 
considered eligible for inclusion in this study if they fulfil all the following criteria; 
(iv) have a PPS (which is medically unexplained) 
(v) are greater than or equal to 18 and less than or equal to 65 years old 
(vi) are registered with a GP practice in South London that has consented to taking part 
in PRINCE Primary 
(vii) have had 6 or more consultations in the last year (not necessarily for the same 
symptom or directly related to PPS) 
(viii) have given written informed consent, provided baseline data before randomisation 
and can speak and read English at a level adequate for participation in the trial. 
Patients will be excluded from the study if the patient has 
(i) active psychosis 
(ii) drug or alcohol addiction as indicated in the patient’s medical notes  
(iii) current benzodiazepine use exceeding the equivalent of 10mg diazepam per 
day 
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(iv) had any psychotherapy treatment within the last year (not inclusive of general 
visits from community psychiatric teams) 
(v) dissociative seizures 
(vi) if they are at imminent risk of self-harm, after psychiatric/ psychological 
assessment 
(vii) taking part in the PRINCE Secondary study or the ACTIB Study.[28] 
Recruitment 
GP Practice Recruitment: Invitation letters will be sent out to GP practices located in South 
London.  If a GP practice is interested, it will be asked to contact the research team for further 
information.  GP practices that fit the eligibility criteria will be enrolled onto the study after 
providing consent to participate.  
Patient Recruitment: GP informatics (i.e. EMIS Web) will be used to identify potential patients 
with PPS from GP practices that agreed to participate in the study.  Prior to the study, the trial 
team liaised with GPs to ensure that the search criterion intended to be uploaded onto EMIS 
web included a range of persistent physical symptoms as well as incorporating elements of 
the trial’s eligibility criteria. For those patients identified in the search, the GP practice 
administration team will send information packs regarding the study and patients will be asked 
to reply to say whether they are interested or not interested in being contacted by the research 
team.  Patients who express an interest will be contacted. 
Study Procedure 
Patients who give their consent to be contacted will be further screened and checked for 
eligibility by the research team.  If the research team is unsure about their diagnosis, they will 
contact their GP and ask for confirmation.  To formally enrol, patients will be required to 
complete and return a signed consent form.  Once consent is obtained, a baseline 
questionnaire pack will be sent to participants four weeks prior to a pre-specified randomisation 
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date.  If participants complete the questionnaire pack before this date they will be fully eligible 
to take part in the study.  Participants will be fully informed that if they do not complete the 
baseline pack before the randomisation date they will not be able to participate in the study.  
GP practices will be randomised on the pre-specified date to one of two arms: ‘integrated GP 
care plus treatment as usual’ or waiting list control (please see figure 1 and section on planned 
intervention for more details).  Participants of GP practices randomised to ‘integrated GP care 
plus treatment as usual’ should be offered the self-help material within 1 week of randomisation 
and GP’s should be offered the training within 2 weeks of randomisation. GP practices 
randomised to the waiting list control arm will continue with treatment as usual until they are 
crossed over at 28 weeks.  Based on these timeframes a training date for all GP practices will 
be scheduled in advance.  However, GP practices will be fully informed that the GP training 
session is dependent on the randomisation outcome i.e. only GP practices randomised to 
integrated GP care will be offered the GP training.  Once randomisation is completed both GP 
practices and participants will be informed of the outcome and this will be week 0 and 
considered the anchor point for this trial for all the participants. Measures will subsequently be 
taken at 12 and 24 weeks. 
The recruitment and study procedures will enable us to investigate a selection of 
feasibility parameters pre-randomisation and identify suitable primary and secondary 
outcomes for future trial evaluations.  See Figure 1 for a flow diagram showing the study 
procedure. 
< Figure 1: Flow Diagram of the Study Procedure about here > 
Randomisation 
Randomisation of the GP practice clusters will take place following recruitment and baseline 
assessments of patients within each GP practice.  The randomisation method will be stratified 
randomisation at the level of the cluster (i.e. GP practice).  The randomisation will be stratified 
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by size of GP practice (≤ 6000 registered patients or > 6000 registered patients).  GP practice 
randomisation will occur in pairs; two GP practices will be randomised at the same time with 
one being randomised to the waiting list control and the other being randomised to ‘integrated 
GP care plus treatment as usual’. Within strata (large or small practices) blocking is used to 
ensure that numbers allocated to either trial arm balance after each block. To avoid being able 
to predict the allocation of a GP practice, practices are randomised as pairs rather than 
sequentially. This ensures that forthcoming allocations cannot be predicted.  Participants will 
have four weeks prior to randomisation to complete the baseline questionnaire pack.  GP 
practice randomisation will be coordinated by an independent randomisation service at the 
UKCRC registered King’s Clinical Trials Unit (KCTU). 
Blinding 
Patients and GPs will not be blind to treatment allocation due to the nature of the trial (i.e. 
therapy trial).  The trial team member responsible for treatment allocation will be unblind.  All 
outcome data are based on self-report and will be collected either by post or email.  The 
research assistant(s) responsible for contacting participants who have not returned or 
completed follow-up questionnaires will be unblind.  Moreover, the Data Monitoring and Ethics 
Committee (DMEC,) research workers and trial statisticians will remain blind to treatment 
allocation.  If unblinding is deemed to be necessary, the trial manager will use the system for 
emergency unblinding through the DMEC. 
Planned intervention: Integrated GP care plus treatment as usual 
Our proposal seeks to develop new care pathways for patients with PPS.   
The intervention ‘Integrated GP care plus treatment as usual’ will include: 
• GP training in utilising cognitive behavioural skills during 10-minute consultations; 
• GP supervision; 
• Audio-visual and written materials/guidelines for GP’s; 
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• Written self-help materials for participants; 
• Animation to illustrate the approach; 
• Integrated case management discussion prior to secondary care referral.  GPs will be 
encouraged to consult with a colleague before making a referral; 
GP Training  
GP training will be delivered at GP practices by clinicians based within King’s Health Partners.  
To inform our decision about length of training we discussed options with the GP’s and offered 
them anything from 1 hour to 1 day training in behaviour change skills.  Most reported that they 
could spare up to 90 minutes as a group given their other commitments.  For this reason, this 
is what we settled upon.  The session will involve a lecture, a role-play demonstrating 
engagement of a patient in a dialogue which focuses on a behaviour change technique and 
discussion.  The specific content of the session will include background information about PPS 
and a three systems model of understanding how symptoms might be perpetuated regardless 
of cause.  The link between symptoms, cognitions and behaviour will be described. The 
emphasis will be on engagement skills and behaviour change interventions, not cognitive re-
structuring, as this is more realistic for GP’s with limited time.  More specifically we will focus 
on techniques that improve sleep routines and the uptake of meaningful activities.  In addition, 
we will demonstrate ways of negotiating the setting of goals that the individual values, as 
homework. We will ask GP’s to utilise these skills and techniques in their consultations.  We 
will not be encouraging the GP to see the participants for additional consultations.  GPs will 
therefore use the approach during routine rather than study-specific consultations.  To ensure 
that GPs are aware of which participants are taking part in PRINCE Primary we will upload a 
file note on the GP practice database for every patient that participates.  This means that if a 
participant has an appointment, the GP will be aware that they are participating in this study.  
GPs will be provided with study-specific guidance on how to change the nature of 
consultations.  Guidance notes and supporting manuals/documentation will be written which 
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are potentially sustainable and suitable for use in other NHS settings.  Information will be 
tailored to the needs of the patient and will be focused on a range of clinical conditions.  
Examples include low back pain, dizziness and headaches. 
A list of helpful responses in the consultation with patients will be provided.  The training 
will be assessed (before and after) in terms of knowledge of PPS and confidence in diagnosing 
and managing these symptoms.  Knowledge will be assessed via ten true- and false questions 
referring to the content of the training.  GPs will also be asked to rate their confidence in 
working with patients with persistent symptoms by responding to a series of pre-specified 
questions, using a Likert scale ranging from 1 (not at all confident) to 7 (very confident).  
Satisfaction with training will be assessed after the training. Open-ended questions will be used 
to elicit feedback about the workshops.  Optional supervision (individual face-to-face, 
Skype/phone and/or group supervision) will be provided to GPs who request additional 
support.  We will assess the uptake of this. Hand-outs will be available for GPs to give to 
participants.  These will be reviewed for ease of reading by service users before the trial starts.   
To summarise we have drawn upon Lee David’s approach to GP education [29] and our 
training will include: 
• How to make use of the cognitive behavioural model in their consultations; 
• How to overcome barriers to using this approach; 
• How to develop their consultation skills; 
• How to use a three systems model to examine relationships between symptoms, 
thoughts and behaviour; 
• How to set an agenda and homework; 
• How to develop a partnership; 
• How to set some behavioural goals; 
• How to facilitate the patient in problem solving. 
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As this intervention does not encourage extra consultations, we recruited frequent attenders 
based on the likelihood that they are more likely to visit their GP, however we cannot be certain. 
This is one reason why ‘integrated GP care plus treatment as usual’ includes sending 
participants booklets (i.e. we are not just providing GPs with materials we are also providing 
self-help materials for participants). 
Participant information booklets 
Participants of GP practices randomised to ‘integrated GP care plus treatment as usual’ will 
be offered a series of booklets based on cognitive behavioural principles via the post.  These 
include, (i) an introduction to PPS, (ii) how to juggle activities, (iii) improving sleep, (iv) living 
with uncertainty, (v) emotional well-being and (vi) goal setting.  Participants will also be sent 
symptom booklets that include information focusing on their primary symptoms.  Furthermore, 
they will also have access to an animation describing a patient’s experience with chronic pain, 
via a website set up specifically for the PRINCE Primary trial. 
Waiting list control: Treatment as Usual 
GP practices randomised to the waiting list control will not be offered ‘integrated GP care’.  
Participants of GP practices randomised to the waiting list control arm will continue with 
treatment as usual.  Treatment as usual is defined as the continuation of standard GP medical 
care for PPS, including usual GP follow-up and pharmacological treatment.  The GP practices 
in the waiting list control arm will be crossed over and offered ‘integrated GP care plus 
treatment as usual’.  The cross over will be at 28 weeks to give 4 weeks to collect measures.  
However, this will not be part of the RCT. 
Feasibility Parameters, Measures and Data Collection Time-points  
The aim of this study is to assess the feasibility of conducting a future evaluation trial to assess 
a new systems approach to PPS in general practice.  Table 1 and Table 2 provide an overview 
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of data collection time-points.  Based on the NIHE’s definition of a feasibility study,[30] the 
PRINCE Primary trial will assess the following feasibility parameters: 
1) Feasibility parameters: 
a) Willingness of GP practices to be contacted about PRINCE Primary (number of GP 
practices responding out of GP practices approached) 
b) Willingness of GP practices to consent and be randomised (number of GP practices 
consenting to participate out of GP practices that responded with an interest to 
participate)  
c) Availability of data needed and the usefulness and limitations of the general practice 
databases (Number of patients identified using GP informatics (search algorithm) out 
of patients registered with the GP practice)  
d) Interest of patients to be contacted about the study (Number of patients responding out 
of patients identified via the search algorithm)  
e) Rate of eligible participants (Number of patients meeting the eligibility criteria out of 
patients who responded with an interest to participate)  
f) Willingness of patients to consent to participate in PRINCE Primary (Number of patients 
consenting to participate out of patients who met the eligibility criteria. 
g) Willingness of participants to complete baseline measures before randomisation 
(Number of participants sending baseline forms back out of participants that provided 
consent) 
h) Interest of GPs to attend the GP training (intervention arm only): (Number of GPs 
attending the GP training out of number of GPs working at the GP practices offering 
training) 
i) Participants follow-up rates to questionnaires per group (Number of participants 
completing questionnaire packs at 12 and 24 weeks respectively out participants 
randomised) 
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2) Measures to identify suitable primary and secondary outcomes for future trial 
evaluations: 
a) Psychosocial Functioning: we will use the 5-item Work and Social Adjustment Scale 
(WSAS)[31] to measure patients’ own perceptions of the impact of PPS on their 
functioning in terms of work, home management, social leisure and private leisure 
activities, and close relationships. 
b)  Physical Symptoms: we will measure the number of symptoms with the PHQ-15[32] 
derived from the Patient Health Questionnaire which reflects DSM-IV diagnoses. 
c) Psychological Distress: mood will be assessed using the 9-item PHQ.[33] 
d) Global Outcome: the adapted Clinical Global Impression (CGI)[34] change score yields 
a self-rated global measure of change and has been used in previous trials of CBT 
interventions. 
e) Satisfaction: we will measure patients’ self-rated satisfaction of the intervention via 
qualitative interviews (i.e. thematic analysis). 
f) Cost Effectiveness (Service): health service use (including hospital attendances and 
admissions, GP contacts), informal care, lost work time and financial benefits will be 
measured via the self-report Client Service Receipt Inventory[35] and the EQ-5D.[36]  
GP medical records will be used as an objective measure to assess the number of 
consultations and medical examinations patients received. 
3) Process Measures: the Cognitive Behavioural Responses Questionnaire (CBRQ)[37] will 
be used to assess potential mechanisms of change. 
4) GPs’ knowledge and confidence: GP training will be evaluated for knowledge, skills and 
confidence using self-reported measures.  GPs who attend the offer of GP training will 
complete this pre and post GP training. 
Qualitative Component 
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Participants who consented to participate in a semi-structured interview (approximately 45 
mins) will be contacted after 28 weeks to give 4 weeks’ time to collect measures.  If the 
participant is still interested a time and date will be arranged to conduct the interview either via 
telephone or face to face. 
The aim of the qualitative interview will be to discuss the participant’s experiences and 
opinions of the intervention, in particular (i) what they thought of the intervention, (ii) how useful 
they found the resources, and (iii) whether they perceived any differences in treatment 
approach during their GP consultation.  Interviews will be audio recorded and transcribed by 
members of the research team using thematic analysis. 
GP’s will also be invited to participate in a semi structured interview (group/individual).  
The aim of the interview will be to discuss GPs experiences of implementing the intervention 
as well as discussing any suggestions on how the intervention can be improved.  Interviews 
will be audio recorded and transcribed by members of the research team using thematic 
analysis. 
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Table 1 Overview of participant assessment moments and outcome measurements  
 Instrument Pre- 
randomisation 
Baseline 12 
weeks  
24 
weeks  
Feasibility Parameters      
Interest of patients to be contacted about the study   x    
Rate of eligible trial participants  x    
Willingness of patients to consent to participate in PRINCE Primary      
Willingness of participants to complete baseline measures before randomisation  x    
Participants follow-up rates to questionnaires per group    x x 
Measures to Identify Suitable Primary Outcomes      
Psychosocial Functioning WASAS  x x x 
Physical Symptoms PHQ-15  x x x 
Psychological Distress PHQ-9  x x x 
Global Outcome  CGI   x x 
Service Use CSRI & EQ-5D-5L  x  x 
Potential Mediators      
Treatment outcome CBRQ  x x x 
WSAS Work and Social Adjustment Scale, PHQ-15 Patient Health Questionnaire 15, PHQ 9 Patient Health Questionnaire 9, CGI Clinical Global Impression, 
CSRI Client Service Receipt Inventory EQ-5D-5L EuroQual 5 Level, CBRQ Cognitive Behavioural Responses Questionnaire
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Table 2 Overview of GP’s/GP Practices assessment moments and outcome measurements 
Outcomes Instrument Pre-randomisation Pre-training Post Training  
Feasibility Parameters     
Willingness of GP practices to be 
contacted about PRINCE Primary  
 x   
Willingness of GP practices to consent 
and be randomised 
 x   
Availability of data needed and the 
usefulness and limitations of the general 
practice databases 
 x   
Interest of GPs to attend the GP training 
(intervention arm only) 
  x  
GP Training Outcomes     
Knowledge and Confidence Self-report  x x 
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Data collection plan: retention 
Retention rates will be maximised by providing participants with the option of completing 
questionnaires via post, telephone or email.  Furthermore, thank you cards will also be sent at 
various stages of the trial. 
Proposed sample size 
A selection of 8-12 GP practices stratified by size (<6000 or > 6000) (clusters) will be recruited, 
with an expected patient sample size of 240.  This would mean that 120 patients will receive 
the integrated GP care by 24 weeks and will complete measures.  As this trial is a feasibility 
study, no formal power calculation has been carried out.  Instead the number of GP practices 
was chosen, such that we have sufficient replicates to estimate feasibility parameters at the 
practice level. 
Data Management 
Data will be collected on paper source data worksheets.  Data will then be entered onto the 
InferMed MACRO online data entry system, on a study-specific database designed and hosted 
at the King Clinical Trial Unit (KCTU).  The system is compliant with Good Clinical Practice 
and FDA 21 CFR Part 11.  Data exports will be provided to the trial statistician upon request. 
The web-based randomisation system will maintain an accurate record of 
randomisations and data can be exported from this system for reports.  Post-randomisation 
data can be readily extracted from the MACRO trial database for the preparation of DMEC 
reports and a front-end search function is available to support data checking and cleaning. 
Central data entry and data cleaning will be undertaken by a designated research 
worker.  Major issues in staff training or data quality will be raised with the trial manager, who 
will perform source data checking against the data collection forms. Discrepancies can be 
raised in the system for resolution by site staff.  Source data verification will be recorded on 
the system and any changes to data subsequent to verification will automatically generate an 
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alert in the system.  Individual user access to the InferMed MACRO system will be co-ordinated 
via the trial manager, who will submit requests to the KCTU. No direct requests from sites will 
be accepted. 
The Chief Investigator will act as custodian for the trial data.  The following guidelines 
will be strictly adhered to; (i) patient data will be pseudo-anonymised (allocation of a unique 
personal identification number (PIN)) and (ii) all pseudo-anonymised data will be stored on a 
password-protected computer.  All trial data will be stored in line with the General Data 
Protection Regulation (GDPR) and archived in line with Sponsor requirements.  Consent forms 
and other paper records will be stored in swipe-card accessed offices in locked filing cabinets. 
Statistical Analysis 
A CONSORT diagram will be constructed including various feasibility parameters: the number 
of eligible practices and patients, number of practices and patients agreeing to enter the trial, 
number of GP practices randomised, then by treatment arm: the number of patients continuing 
through the trial, the number withdrawing from the study at various time points. The feasibility 
parameters will be estimated using the CONSORT diagram and will be presented as 
proportions accompanied by 95% confidence intervals (CI) to provide a measure of estimator 
precision. 
Inferential analyses will be used to estimate intervention effects in terms of outcome 
variables.  The formal statistical analyses will estimate the difference in mean outcomes 
between patients from GP practices randomised to ‘integrated GP care plus treatment as 
usual’ and waiting list control by intention to treat at 12 and 24 weeks follow up.  We will provide 
estimates of trial arm differences with associated 95% confidence intervals and will also 
translate these effects into standardised effects sizes to enable comparisons across measures 
and time points.  This information can help the planning of a future evaluation trial by providing 
guidance as to promising outcome measures and likely effect sizes.  No formal significance 
testing will be carried out. Standardised effect sizes will be calculated by dividing estimated 
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mean differences by the respective baseline standard deviations (SDs).  Analysis will be based 
on the intention-to-treat principle and we plan to use linear mixed modelling with maximum 
likelihood (ML) estimation. A random effect for participant will be entered in the model to 
account for correlations between repeated measures. Additionally, a random effect for cluster 
will also be included to allow for correlations between patients within a practice.  Bias in 
estimates of trial arm differences will be avoided by use of randomisation and blinding of the 
outcome assessors. 
All efforts will be made to avoid missing baseline data (i.e. requiring completion of 
baseline data before randomisation), but missing values will be imputed according to current 
recommendations.[38]  Missing scale item data will be handled as per questionnaire specific 
recommendations.  We will aim to support participating practices to minimise loss to follow-up 
by encouraging a number of approaches: adopting other evidence-based procedures for 
recruiting and maintaining participation in the study and encouraging patients to return 
outcome measures (e.g. contacting people before sending out questionnaires, sending 
personalised cover letters using colour printing, and keeping measures short in terms of 
completion time).[39, 40] 
Health Economics 
The main objective of the health economic aspect of the feasibility study is to assess what 
services are being used and this will inform the collection of service use data in a full trial. 
Data Monitoring 
The Programme Management Group (PMG) will be responsible for ensuring the appropriate, 
effective and timely implementation of the study.  The Data Monitoring and Ethics Committee 
(DMEC) and Programme Steering Committee (PSC) have been formed as independent 
committees to oversee the study.  The committees will be responsible for the independent 
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oversight of the progress of the trial, the investigation of Serious Adverse Events (SAEs) and 
for determination of trial progress. 
Procedures for Recording and Reporting Serious Adverse Events 
Adverse events are any clinical change, disease or disorder experienced by the participant 
during their participation in the trial, whether or not considered related to the use of treatments 
being studied in the trial.  Any SAEs, Serious Adverse Reaction (SAR) or Suspected 
Unexpected Serious Adverse Reaction (SUSAR) will be recorded by the research worker at 
12 and 24 weeks post baseline.  An adverse event is defined as serious if it: 
• results in death; 
• is life-threatening (with an immediate not hypothetical risk of death at the time of the 
event); 
• requires hospitalisation (but not including elective hospitalisation for pre-existing 
condition); 
• results in a new persistent or new significant disability or incapacity defined as: 
i. Severe = a significant deterioration in the participant’s ability to carry out their 
important activities of daily living (e.g. employed person no longer able to work, 
caregiver no longer able to give care, ambulant participant becoming bed 
bound); 
ii. Persistent = 4 weeks continuous duration; 
• Any other important medical condition which, though not included in the above, may 
jeopardise the participant and may require medical or surgical intervention to prevent 
one of the outcomes listed;  
• Any new episode of deliberate self-harm. 
We will require two clinically trained scrutinisers to review all serious adverse events and 
reactions, independently from the trial team.  They will be blind to the treatment group and will 
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be required to establish whether events reported constituted serious adverse events.  The 
scrutinisers would then be unblinded to treatment allocation so that they can then establish 
whether any serious adverse events were serious adverse reactions to the system approach. 
Stopping Rules 
The trial may be prematurely discontinued by the Sponsor or Chief Investigator on the basis 
of new safety information or for other reasons given by the DMEC/PSC or Research Ethics 
Committee (REC) concerned.  The trial may also be prematurely discontinued due to lack of 
recruitment or upon advice from the PSC (if applicable), who will advise on whether to continue 
or discontinue the study and make a recommendation to the sponsor.  If the study is 
prematurely discontinued, active participants will be informed and no further participant data 
will be collected. 
Auditing 
The investigator(s) will permit trial-related monitoring, audits and REC review by providing the 
sponsor(s) and REC direct access to source data and other documents.  Monitoring of this 
study will be to ensure compliance with Good Clinical Practice and scientific integrity will be 
managed by the study team.  The study will be compliant with the research governance 
framework and MRC Good Clinical Practice Guideline.[41]  We will institute a rigorous 
programme of quality control.  The trial manager will be based at the Institute of Psychiatry, 
Psychology and Neuroscience, King’s College London and line-managed and supervised by 
the chief investigator.  The trial manager will prepare study specific Standard Operating 
Procedures (SOPs) for the study.  The trial manager will supervise a designated research 
worker to undertake data management/cleaning, so that they can provide regular reports on 
data quality to the chief investigator and the other co-applicants.  Quality assurance checks 
will be undertaken by the trial team to monitor the level of missing data and timeliness of data 
entry and check for illogical or inconsistent data.  The trial manager will monitor data collection 
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procedures, ensure that study data entry procedures are followed and undertake source data 
verification against the paper data collection forms.  The trial statisticians will be affiliated with 
KCTU, and will be responsible for producing DMEC reports, drafting of the Statistical Analysis 
Plan (SAP) and for carrying out primary analyses. We will ask the DMEC to take on this role 
of monitoring participating GP practices at recruitment.  Our KCTU has SOPs that guide the 
trial statistician’s reporting to the DMEC. 
Patient and Public Involvement 
In the early stages of this study we developed links with key stakeholders including patients 
with persistent physical symptoms, commissioners and a national charity.    The first meeting 
entailed an open discussion to ensure that the trial was not burdensome for patients and to 
also gain a better understanding of what GP’s felt was possible.   We continue to involve these 
stakeholders during the study. Patients were not involved with the recruitment of participants 
into the study.  Peer reviewed results will be disseminated to participating GP practices and 
study participants. 
ETHICS AND DISSEMINATION 
Ethical and Research Governance Approval 
This feasibility study is funded by Guy’s and St Thomas’ Charity.  Ethical approval has been 
granted by the Camberwell St Giles Ethics Committee (Reference 15/LO/0057) and King’s 
College London and South London and Maudsley (SLaM) Hospital will act as sponsors for the 
research.  The study will be managed via a central co-ordinating team.  The study was also 
submitted to NHS Clinical Research Network, South London for research governance and 
approval was received on 13th April 2015. 
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Confidentiality 
All patient data will be pseudo-anonymised.  All pseudo-anonymised data will be stored on a 
password-protected computer.  All trial data will be stored in line with the Data Protection Act.  
Consent forms and other paper records will be stored in locked filing cabinets within swipe-
card access offices. 
Insurance / Indemnity 
Standard procedures for insurance of University and NHS employees and sites, and NHS 
patients will apply. 
Dissemination Policy 
We anticipate that there will be different target audiences for our dissemination activities: 
a. Professionals: we will disseminate findings to healthcare professionals (e.g. 
rheumatologists/ neurologists/cardiologists, psychiatrists, GPs, nurses, psychologists, 
CBT Therapists) via papers in high impact peer reviewed journals and presentations at 
local, national and international scientific meetings.  We will also disseminate findings 
via the recently established UK Functional Neurological Symptoms (UKFNS) group.  
Findings will also be presented at the British Association of Behavioural and Cognitive 
Psychotherapies (BABCP) conference and GP Conferences within the UK.  We will 
make available written materials and offer training workshops for other NHS clinical 
services, and at meetings if appropriate. 
b. Service planners and commissioners: if our study is successful, we anticipate that our 
findings will have relevance for the provision of care for patients with PPS, and therefore 
we will disseminate our findings to those who plan and commission care for people with 
PPS. 
c. Voluntary sector: we will make our findings available to PPS charities, which already 
disseminate information on PPS.  We will offer summaries of our findings to websites for 
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the public which already provide information on PPS and to charities offering information 
on other MUS but not currently PPS, 
DISCUSSION 
This cluster randomised waiting list, controlled trial aims to investigate the feasibility of 
an integrated GP care approach plus treatment as usual for patients with PPS in 
primary care versus waiting list control.  The intervention primarily operates at the GP 
practice (cluster) level and hence a cluster randomised trial design is employed.  This 
means GP practices randomised to ‘integrated GP care plus treatment as usual’ will 
include (i) GP training in cognitive behavioural skills, (ii) GP supervision, (iii) audio 
visual material for GPs and (iv) self-help materials for participants.  GP practices 
randomised to the waiting list control arm will continue with treatment as usual (i.e. GP 
practices will not be offered the intervention’ initially but will be crossed over and 
offered the intervention at 28 weeks to give 4 weeks’ time to collect measures).  Cluster 
randomised trials can be subject to selection bias when patients are recruited after 
allocation of the intervention to the clusters (GP practices). Hence our design ensures 
that patients are recruited before their GP practice is randomised so their decision to 
take part in the trial cannot be informed by knowledge of whether the GP practice 
receives the intervention.  To avoid participants having to wait a long time only those 
who frequently attended their GP will be eligible to participate in this study (please see 
eligibility criteria).  Patients will not be dropped if they are not seen by a trained GP as 
the integrated care approach also includes self-help materials for patients.  This study 
aims to mimic a real-life setting in which a patient may not see the same GP on a 
regular basis. 
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 Given the prevalence of PPS and their costs to health services, there is an urgent need 
to develop easily accessible and affordable treatments for this patient group.  Although 
previous studies have examined the efficacy of CBT-based approaches in treating patients 
with PPS, most studies were conducted in secondary care and focused on specific 
conditions.[14, 15]  Taken together, evidence suggests positive effects of CBT-based group 
intervention on PPS.  However, group interventions and bringing in secondary care healthcare 
professionals may not always be feasible and time-efficient.  The present trial attempts to 
address these challenges by evaluating the feasibility of training GPs in delivering behaviour 
change interventions in a 10-minute consultation and providing patients with self-help 
materials. 
 There are limitations to this study.  It is unlikely that all GPs will attend all of the training.  
However, we will organise the training at times that suit as many GPs as possible.  We cannot 
be sure in any case that GPs will utilise the skills they may have acquired during the training.  
GPs consultations will not be recorded as GP’s themselves feel it is too burdensome.  In order 
to mitigate these shortcomings, we will conduct semi-structured qualitative interviews with a 
random selection of patients to assess whether they had seen a GP and whether they felt that 
a behaviour change intervention had been delivered. 
 In conclusion, this RCT aims to assess the feasibility of an integrated GP approach for 
treating patients with PPS. Based on the results of the study, a fully-powered RCT will be 
considered in order to assess the clinical effectiveness of this approach in changing identified 
health-related outcomes. 
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